I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 4 studies | 21% ± 2% | |
| astrocyte | 3 studies | 25% ± 6% | |
| oligodendrocyte precursor cell | 3 studies | 25% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 4 studies | 21% ± 2% | |
| astrocyte | 3 studies | 25% ± 6% | |
| oligodendrocyte precursor cell | 3 studies | 25% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 29% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 1094.27 | 245 / 245 | 100% | 9.32 | 502 / 502 |
| brain | 100% | 490.54 | 2629 / 2642 | 100% | 13.56 | 705 / 705 |
| esophagus | 100% | 621.42 | 1443 / 1445 | 99% | 6.59 | 181 / 183 |
| intestine | 100% | 820.25 | 966 / 966 | 98% | 7.14 | 517 / 527 |
| skin | 100% | 709.79 | 1801 / 1809 | 97% | 8.91 | 458 / 472 |
| pancreas | 100% | 850.81 | 327 / 328 | 97% | 4.98 | 172 / 178 |
| stomach | 100% | 669.44 | 358 / 359 | 96% | 6.54 | 274 / 286 |
| breast | 100% | 787.43 | 457 / 459 | 96% | 5.96 | 1072 / 1118 |
| bladder | 100% | 786.86 | 21 / 21 | 94% | 5.56 | 475 / 504 |
| ovary | 100% | 2080.47 | 180 / 180 | 93% | 5.78 | 400 / 430 |
| adrenal gland | 100% | 870.91 | 258 / 258 | 92% | 5.03 | 212 / 230 |
| lung | 97% | 464.84 | 561 / 578 | 94% | 5.35 | 1085 / 1155 |
| uterus | 100% | 1059.12 | 170 / 170 | 91% | 5.70 | 416 / 459 |
| kidney | 100% | 598.98 | 89 / 89 | 91% | 6.18 | 816 / 901 |
| thymus | 100% | 747.78 | 653 / 653 | 87% | 3.70 | 524 / 605 |
| liver | 100% | 572.37 | 225 / 226 | 86% | 4.56 | 348 / 406 |
| adipose | 100% | 764.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1058.70 | 241 / 241 | 0% | 0 | 0 / 0 |
| muscle | 100% | 818.07 | 801 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 99% | 663.20 | 1327 / 1335 | 0% | 0 | 0 / 0 |
| heart | 98% | 516.26 | 842 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 4.68 | 28 / 29 |
| eye | 0% | 0 | 0 / 0 | 96% | 6.80 | 77 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 91% | 4.54 | 41 / 45 |
| peripheral blood | 45% | 183.64 | 421 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0031365 | Biological process | N-terminal protein amino acid modification |
| GO_0018206 | Biological process | peptidyl-methionine modification |
| GO_0006508 | Biological process | proteolysis |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0004239 | Molecular function | initiator methionyl aminopeptidase activity |
| GO_0008235 | Molecular function | metalloexopeptidase activity |
| GO_0070006 | Molecular function | metalloaminopeptidase activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0004177 | Molecular function | aminopeptidase activity |
| Gene name | METAP1D |
| Protein name | Methionine aminopeptidase 1D, mitochondrial (MAP 1D) (MetAP 1D) (EC 3.4.11.18) (Methionyl aminopeptidase type 1D, mitochondrial) (Peptidase M 1D) |
| Synonyms | MAP1D |
| Description | FUNCTION: Removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Requires deformylation of the N(alpha)-formylated initiator methionine before it can be hydrolyzed (By similarity). May play a role in colon tumorigenesis. . |
| Accessions | Q6UB28 ENST00000315796.5 ENST00000709703.1 |
